#Canada #Aurora Cannabis #Edmonton #Curaleaf #hostile bid

Aurora Cannabis Reaffirms Stance Against Hostile Bid from Curaleaf

On October 14, 2026, Aurora Cannabis Inc., a prominent Canadian leader in the medical cannabis sector, once again advised its shareholders to reject the hostile bid presented by Curaleaf Holdings, Inc. This decision stems from the unanimous recommendation of a special committee of independent directors, which evaluated the offer and found it significantly undervalues the company.

Context of the Hostile Bid

Curaleaf, a well-known player in the cannabis industry, had earlier issued a revised offer, which Aurora contends fails to address numerous concerns previously raised by its Board. The company's Board of Directors argues that accepting the offer would mean surrendering their shareholder's equity at a bargain price, undermining Aurora's robust position in the market, which boasts a debt-free status and healthy cash reserves.

Miguel Martin, Aurora’s Executive Chairman and CEO, emphasized, “Curaleaf's revised offer still does not reflect the value of the company Aurora shareholders own today.” He highlighted that the bid included a substantial portion of Aurora's resources, essentially requiring shareholders to fund the acquisition themselves, without fair compensation valuation.

Importance of Strategic Review

In light of the hostile bid, Aurora's Special Committee is actively exploring various strategic alternatives aimed at maximizing shareholder value. Their ongoing evaluation process could lead to better opportunities that might present themselves in the future. The committee hopes to identify a strategic direction that can yield a more advantageous outcome than merely succumbing to the current hostile offer that remains on the table until December 4, 2026.

The Board has concluded that the stakes of the current offer are high, noting that engaging with this bid could diminish the chances of uncovering a superior solution. As such, they have called upon shareholders to exercise patience and refrain from any immediate actions that could close off potentially promising options.

Concerns Over Curaleaf’s Offer

Several key reasons fuel Aurora's recommendation to reject Curaleaf’s offer:
1. Inadequate Valuation: The bid is considered to undervalue the company based on various metrics, a viewpoint supported by an updated financial assessment from its advisors that deems the offer inadequate from a financial perspective.
2. Risk to Shareholders: Accepting the offer could expose Aurora shareholders to risks associated with holding Curaleaf shares, which have been inflated in valuation.
3. Opportunistic Nature: The review highlights that the intention behind the offer seems to be an opportunistic acquisition of Aurora's assets without a sincere reflection of their long-term earning potential.
4. Inadequate Synergy Justification: Curaleaf has yet to convincingly demonstrate that the estimated synergies from the merger would satisfactorily benefit Aurora's shareholders, suggesting that any potential advantages would instead cater primarily to Curaleaf’s existing shareholders.

Given these factors, the Board and the Special Committee believe it is in the best interests of shareholders to allow time for alternative strategies to be explored. The ongoing assessment should lead to more options that could better meet the needs and interests of those invested in Aurora.

Conclusion and Next Steps

As Aurora continues to navigate these turbulent waters, shareholders are being encouraged to stay informed and involved. Kingsdale Advisors, serving as the Company’s strategic advisor, remains available to answer any questions or to provide assistance during this transitional phase. Shareholders can anticipate further information regarding the strategic process and future recommendations that may arise from the Board’s efforts to safeguard and elevate shareholder value. Furthermore, adhering to the Special Committee's advice to take no immediate actions will help keep options open as the situation evolves.

Aurora Cannabis remains steadfast in its commitment to enhancing its performance and delivering significant value to its shareholders while navigating the complexities of industry consolidations and market fluctuations. For additional insights and updates, stakeholders are encouraged to visit Aurora's dedicated webpage at ProtectAurora.com.